Daiichi-Sankyos Angiotensin II 1 antagonist olmesartan reverses blood vessel damage « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
June 2008

M T W T F S S

« May Jul »

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

Daiichi-Sankyos Angiotensin II 1 antagonist olmesartan reverses blood vessel damage

Posted on June 17, 2008 by crimsoncanary

Olmesartan medoxomil has been found to be effective at reversing the narrowing of the arteries that occurs in patients with hypertension. Treatment improved structural abnormalities of resistance arteries.

Filed under: gpcr | Tagged: Angiotensin II AT1, Benicar, Daiichi-Sankyo, Olmesartan

« Takeda to appeal EU negative opinion on melatonin agonist ramelteon Phase III initiated in Cogentus clopidogrel/omeprazole combination treatment trial »

Leave a Reply